WO2020077397A1 - Procédés et compositions pour le traitement de lésions des muqueuses - Google Patents

Procédés et compositions pour le traitement de lésions des muqueuses Download PDF

Info

Publication number
WO2020077397A1
WO2020077397A1 PCT/AU2019/051117 AU2019051117W WO2020077397A1 WO 2020077397 A1 WO2020077397 A1 WO 2020077397A1 AU 2019051117 W AU2019051117 W AU 2019051117W WO 2020077397 A1 WO2020077397 A1 WO 2020077397A1
Authority
WO
WIPO (PCT)
Prior art keywords
flightless
expression
subject
mrna
activity
Prior art date
Application number
PCT/AU2019/051117
Other languages
English (en)
Inventor
Allison June Cowin
Zlatko KOPECKI
Original Assignee
Abregen Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018903891A external-priority patent/AU2018903891A0/en
Application filed by Abregen Pty Ltd filed Critical Abregen Pty Ltd
Publication of WO2020077397A1 publication Critical patent/WO2020077397A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases

Abstract

La présente invention concerne le traitement de lésions des muqueuses dans le tractus gastro-intestinal. Plus particulièrement, l'invention concerne des procédés et des compositions pharmaceutiques pour le traitement d'une lésion des muqueuses associée à un trouble du tractus gastro-intestinal. Les procédés comprennent l'administration à un sujet d'une quantité efficace d'un agent qui diminue l'expression et/ou l'activité de la Flightless I chez le sujet. Le traitement de troubles tels que la maladie intestinale inflammatoire (y compris la recto-colite hémorragique et la maladie de Crohn), la maladie cœliaque, la maladie d'ulcère gastroduodénal et l'iléite régionale est envisagé. L'invention concerne également des procédés et des kits associés pour diagnostiquer un trouble du tractus gastro-intestinal ou pour évaluer l'évolution d'un trouble du tractus gastro-intestinal chez un sujet.
PCT/AU2019/051117 2018-10-15 2019-10-15 Procédés et compositions pour le traitement de lésions des muqueuses WO2020077397A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018903891 2018-10-15
AU2018903891A AU2018903891A0 (en) 2018-10-15 Methods and compositions for the treatment of mucosal lesions

Publications (1)

Publication Number Publication Date
WO2020077397A1 true WO2020077397A1 (fr) 2020-04-23

Family

ID=70282852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2019/051117 WO2020077397A1 (fr) 2018-10-15 2019-10-15 Procédés et compositions pour le traitement de lésions des muqueuses

Country Status (1)

Country Link
WO (1) WO2020077397A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007048202A1 (fr) * 2005-10-25 2007-05-03 Women's & Children's Health Research Institute Méthodes et compositions pour moduler la cicatrisation de plaies
WO2014100852A1 (fr) * 2012-12-24 2014-07-03 Royal Melbourne Institute Of Technology Inhibition de la croissance du cancer et de métastase
WO2016172769A1 (fr) * 2015-04-29 2016-11-03 University Of South Australia Compositions et méthodes pour l'administration d'anticorps

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007048202A1 (fr) * 2005-10-25 2007-05-03 Women's & Children's Health Research Institute Méthodes et compositions pour moduler la cicatrisation de plaies
WO2014100852A1 (fr) * 2012-12-24 2014-07-03 Royal Melbourne Institute Of Technology Inhibition de la croissance du cancer et de métastase
WO2016172769A1 (fr) * 2015-04-29 2016-11-03 University Of South Australia Compositions et méthodes pour l'administration d'anticorps

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOPECKI, Z. ET AL.: "Flightless I exacerbation of inflammatory responses contributes to increased colonic damage in a mouse model of dextran sulphate sodium-induced ulcerative colitis", SCIENTIFIC REPORTS, vol. 9, no. 1, 5 September 2019 (2019-09-05), pages 12792, XP055703236 *

Similar Documents

Publication Publication Date Title
Seo et al. Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease
Marinelli et al. Schwann cell autophagy counteracts the onset and chronification of neuropathic pain
Sato et al. Urine podocyte mRNAs mark progression of renal disease
Qing et al. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury
Germán et al. Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis
JP2008545437A (ja) 炎症性腸疾患についての末梢血単核細胞の発現プロフィール
US20180207234A1 (en) Inhibition of cancer growth and metastasis
US20190072541A1 (en) Biomarkers for treatment of alopecia areata
JP2018506528A (ja) Ｉｂｄにおける治療標的及びバイオマーカー
US20230218713A1 (en) Debaryomyces species as an indicator of non-healing ulcers in crohn's disease
JP2021511019A (ja) 関節リウマチ（ｒａ）の処置のための診断方法及び治療方法
CN114364693A (zh) 代谢性疾病的治疗和预防
JP2009515542A (ja) 脊髄損傷における抗Ｎｏｇｏ−Ａ抗体処置のためのバイオマーカー
EP2771687A2 (fr) Il-19 utilisée comme biomarqueur du traitement anti-tslp
WO2020077397A1 (fr) Procédés et compositions pour le traitement de lésions des muqueuses
Montrose et al. Colonoscopic-guided pinch biopsies in mice as a useful model for evaluating the roles of host and luminal factors in colonic inflammation
WO2016040987A1 (fr) Traitement et/ou prévention de psoriasis
US20240156913A1 (en) Treatment and prevention of metabolic diseases
Hughes Surveying the epigenetic landscape of murine synovitis to explore the heterogeneity of rheumatoid arthritis
WO2015000022A1 (fr) Traitement et prévention d'une mastite
TW202402790A (zh) 減少呼吸系統感染之方法
JP2023055804A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
JP2022500382A (ja) 膵炎を処置するための方法
Shimizu et al. Clinical and Pathological Analysis of Transplant Glomerulopathy Cases.: Abstract# A245
Cowin Z. Kopecki, G. Yang1, S. Treloar3, S. Mashtoub4, 5, GS Howarth2, AG Cummins6 &

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19874471

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19874471

Country of ref document: EP

Kind code of ref document: A1